|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adventrx Pharmaceuticals Inc., of San Diego, reported a 63 percent overall clinical benefit and a 38 percent objective response rate in measurable Phase II patients treated with CoFactor and 5-fluorouracil as a first-line treatment of metastatic colorectal cancer. Patients exhibited no grade 3 or 4 gastrointestinal or hematological toxicities. The company expects to announce final results in the fourth quarter.
o Alexion Pharmaceuticals Inc., of Cheshire, Conn., said results of a new study show that treatment with an anti-C5 complement blocking antibody reduced the bronchial inflammation and airway constriction that prompts asthma's symptoms. The study was ...